化合物 T10895
| 中文名称 | 化合物 T10895 |
|---|---|
| 中文同义词 | 化合物 T10895;化合物CSN5I-3;3-(二氟甲基)-N-(6-((5S,6S)-6-羟基-6,7,8,9-四氢-5H-咪唑并[1,5-A]氮杂卓-5-基)-[1,1'-联苯]-3-基)-1-异丙基-1H-吡唑-5-甲酰胺;化合物CSN5I-3,10 MM DMSO 溶液;CSN5I-3(MCE HY-112134);3-(二氟甲基)-N-(6-((5S,6S)-6-羟基-6,7,8,9-四氢-5H-咪唑并[1,5-a]氮杂卓-5-基)-[1,1'-联苯]-3-基)-1-异丙基-1H-吡唑-5-甲酰胺 |
| 英文名称 | 1H-Pyrazole-5-carboxamide, 3-(difluoromethyl)-1-(1-methylethyl)-N-[6-[(5S,6S)-6,7,8,9-tetrahydro-6-hydroxy-5H-imidazo[1,5-a]azepin-5-yl][1,1'-biphenyl]-3-yl]- |
| 英文同义词 | 1H-Pyrazole-5-carboxamide, 3-(difluoromethyl)-1-(1-methylethyl)-N-[6-[(5S,6S)-6,7,8,9-tetrahydro-6-hydroxy-5H-imidazo[1,5-a]azepin-5-yl][1,1'-biphenyl]-3-yl]-;3-(Difluoromethyl)-N-(6-((5S,6S)-6-hydroxy-6,7,8,9-tetrahydro-5H-imidazo[1,5-a]azepin-5-yl)-[1,1'-biphenyl]-3-yl)-1-isopropyl-1H-pyrazole-5-carboxamide;CSN5i-3, 10 mM in DMSO;3-(Difluoromethyl)-N-(6-((5S,6S)-6-hydroxy-6,7,8,9-tetrahydro-5H-imidazo[1,5-a]azepin-5-yl)-[1,1'-biphenyl]-3-yl)-1-isopropyl-1H-pyrazole-5-carboxamide |
| CAS号 | 2375740-98-8 |
| 分子式 | C28H29F2N5O2 |
| 分子量 | 505.56 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 2375740-98-8.mol |
| 结构式 |  |
化合物 T10895 性质
| 沸点 | 666.5±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.35±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C, protect from light, stored under nitrogen |
| 溶解度 | DMSO：50.56（最大浓度 mg/mL）；100.0（最大浓度 mM） |
| 形态 | 固体 |
| 酸度系数(pKa) | 12.66±0.70(Predicted) |
| 颜色 | 浅黄至黄色 |
CSN5i-3 是一种有效的，选择性和口服的 CSN5/Jab1 抑制剂，抑制 CSN 催化的 Cul1 deneddylation IC50 值为 5.8 nM。
IC50: 5.8 nM (CSN5)
CSN5i-3 traps CRLs in the neddylated state, which leads to inactivation of a subset of CRLs by inducing degradation of their substrate recognition module.
CSN5i-3 shows a good pharmacokinetic profile. CSN5i-3 inhibits growth of human xenograft. Treatment with CSN5i-3 triggers the formation of cleaved PARP and cleaved caspase 3 indicative of apoptosis induction.